MedTrace Logo

Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections

NCT06096025 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-07-04

No results posted yet for this study

Summary

Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.

Conditions

  • Streptococcus Pneumoniae

Interventions

DRUG

pneumoniae bacteremia therapy

To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Matthew Crotty, PharmD · Methodist Midlothian Medical Center

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-23
Primary Completion
2026-06-23
Completion
2026-06-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06096025 on ClinicalTrials.gov